| Document |
Document Title |
|
WO/2024/106006A1 |
The present invention provides an insect in which the total amount of amino acids is increased and/or the amino acid composition is different compared to a wild type of the insect. In the insect according to the present invention, the am...
|
|
WO/2024/106448A1 |
The nucleic acid construct according to the present invention has such a structure that a protein can be expressed by the occurrence of at least two times of a recombinant reaction by single-strand annealing (SSA), is useful for the diag...
|
|
WO/2024/107636A2 |
The present invention relates to antisense oligonucleotides (ASOs) used to treat, prevent or ameliorate the progression of conditions such as Type 2 Diabetes Mellitus (T2DM) and insulin resistance, leptin resistance and obesity, Rett syn...
|
|
WO/2024/107836A1 |
Provided herein are nucleic acid molecules that include (a) an effector RNA; (b) an escape module; and (c) a stabilization module, wherein the effector RNA includes a CRISPR guide RNA (gRNA), a small RNA, a complementary RNA, a nuclear R...
|
|
WO/2024/106568A1 |
The present invention relates to a novel recombinant nucleic acid molecule where a bioluminescence enzyme gene is linked to downstream of the transposable element in an inverted direction with being disrupted by an artificial intron. Thi...
|
|
WO/2024/103615A1 |
Provided is a high-specific-activity acidic mannanase mutant. The mutant comprises at least one mutation site of F46S/Q, Y132F, T148K/R, F223L/W/M, L259M, S263E/T/D, W264F/Y/M/V, T266F/K/Y/L/G/Q, P335Q/E/K/T, and D336G. The specific acti...
|
|
WO/2024/104433A1 |
Provided are use of galectin-1 (Gal-1) as an immune checkpoint in the preparation of a tumor immunotherapy medicament and the medicament, and provided is a new tumor immunotherapy strategy targeting the new immune checkpoint. Lactose and...
|
|
WO/2024/107723A2 |
Disclosed herein are compositions comprising allogeneic, hypoimmunogenic cell-targetable biomimetic nanovesicles (BioNVs) and methods of using the same for the treatment of hemophagocytic lymphohistiocytosis (HLH) and HLH-associated dise...
|
|
WO/2024/107985A2 |
The present disclosure provides improved adenoviral helper plasmids for the production of recombinant adeno-associated viruses.
|
|
WO/2024/103117A1 |
The present invention provides a library screening method for identifying protein- protein interactions, or protein-polynucleotide interactions, in a plant protoplast.
|
|
WO/2024/107539A2 |
Methods and bioreactors are used to produce triacetic acid lactone by thiolase BktB from Burkholderia.
|
|
WO/2024/106203A1 |
Provided is a DNA construct that holds two long intergenic regions (LIRs) derived from a geminivirus, the DNA construct being such that a site for insertion of a target DNA is positioned between the two LIRs, and no short intergenic regi...
|
|
WO/2024/108055A1 |
Nucleic acids and viral vectors, particularly adeno-associated virus (AAV) vectors are provided that encode Cas9 and paired guide RNAs. The nucleic acids and vectors, and compositions that comprise them, can be used in methods to treat s...
|
|
WO/2024/108216A1 |
Compositions and methods for the management and treatment of obesity, metabolic disorders, nausea and emesis using a ODN peptides and synthetic derivatives thereof are disclosed.
|
|
WO/2024/105638A1 |
The present invention discloses gene therapy vectors for treatment of Hunter Syndrome. The gene therapy vector expresses a fusion protein comprising at least one anti-hTfR1 VHH antibody fused to a human iduronate -2-sulfatase.
|
|
WO/2024/105063A1 |
The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of an USH2A related disease or condition.
|
|
WO/2024/107932A1 |
A method any system for performing optical PCR. The method includes binding nucleic acids in a sample fluid bind to a solid-phase substrate. The method also includes flowing the sample fluid in a fluid conduit to a trapping site. The tra...
|
|
WO/2024/106783A1 |
The present invention relates to polydeoxyribonucleotide (PDRN)-containing exosomes, a composition including same, and a preparation method therefor, wherein the PDRN-containing exosomes of the present invention are derived from a fish t...
|
|
WO/2024/105162A1 |
Type II Cas proteins, for example Type II Cas proteins referred to as AHZW, ABSE, AIXM, AXTQ, AIWM, AIWR, AIYQ, EQSC, BDLP, and BDKL Type II Cas proteins; gRNAs for Type II Cas proteins; systems comprising Type II Cas proteins and gRNAs;...
|
|
WO/2024/107742A1 |
The present disclosure provides compositions of genetically modified cells that are hypoimmunogenic. The present disclosure also provides methods of making hypoimmunogenic cells and using hypoimmunogenic cells for the treatment of cancer...
|
|
WO/2024/106421A1 |
The present invention addresses the problem of providing a method for collecting miRNA with high yield. The aforementioned problem is solved by a method for collecting miRNA from a liquid specimen collected from a subject, said method in...
|
|
WO/2024/107984A1 |
The disclosure provides methods of purifying adeno-associated virus (AAV) particles by introducing a flocculant step into a large scale a manufacturing process, thereby improving AAV particle purity and yield.
|
|
WO/2024/103822A1 |
Provided are a polypeptide and a related nucleic acid product and enzyme product thereof, a preparation method therefor, and an application thereof in the production of lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT). The polypepti...
|
|
WO/2024/108217A1 |
The present disclosure provides methods and compositions for treating or preventing diastolic dysfunction and/or diastolic heart failure in a human subject, comprising administering to the subject an oligonucleotide that suppresses the e...
|
|
WO/2024/106538A1 |
The present invention provides: a lymphocyte cleansing method that involves cleansing lymphocytes with a bicarbonate ion–containing physiological aqueous solution; a lymphocyte cryopreservation method that involves suspending and freez...
|
|
WO/2024/107652A1 |
A formulation comprising an oligonucleotide selected from the group consisting of an oligonucleotide having one of SEQ ID No. 1 through SEQ ID No. 23 or a variant thereof. Also, a method of prophylactic treatment of progressive muscle at...
|
|
WO/2024/103631A1 |
Provided is a construction method for a transgenic mouse with a GGC repeat expansion mutation in a NOTCH2NLC gene, comprising the following steps: constructing an F0-generation positive mouse with a LoxP sequence and site-specific knock-...
|
|
WO/2024/107683A1 |
The treatment or prevention of a disease characterized by deposition of amyloid beta (Aβ) plaques in the brain of a human subject, in particular intravenous and subcutaneous doses and dosing regimens of anti-N3pG antibodies.
|
|
WO/2024/104373A1 |
Provided are affinity-maturated single domain anti-PD-L1 antibodies and polypeptides, such as multispecific antibodies and chimeric antigen receptors, that include these single domain antibodies. These antibodies, including their humaniz...
|
|
WO/2024/107598A1 |
Methods and compositions for identifying, selecting and/or producing a pathogen resistant plant, plant cell or seed (e.g., a legume or soybean plant, plant cell or seed) are provided. Polynucleotides and polypeptides are provided, which ...
|
|
WO/2024/103251A1 |
The present application relates to an anti-AFP/HLA02 TCR-like antibody and the use thereof. The antibody can specifically bind to a human AFP158-166/HLA-A02*01* complex with a KD value of about 3.1E-09M or less. The present application f...
|
|
WO/2024/105114A1 |
The invention relates to methods and materials for use in treating neurodegenerative diseases associated with pathological protein aggregates and provides fusion proteins comprising: (i) a first portion comprising a sequence of a protein...
|
|
WO/2024/106916A1 |
The present invention relates to a method for purifying compound K from a microbial fermentation broth, the method comprising: (a) a step of culturing a microorganism expressing compound K to obtain a microbial fermentation broth; (b) a ...
|
|
WO/2024/105673A1 |
The present invention is directed to, inter alia, a method for treating retinal disease using a splicing modulator, such as an antisense oligonucleotide, capable of inducing the native splicing of exon 6 of a mutant nuclear receptor subf...
|
|
WO/2024/103728A1 |
The present invention relates to an anti-poxvirus vaccine, which comprises an mRNA molecule encoding the following proteins and/or fusion proteins: (a) more than one monkey poxvirus protein selected from the following: an A35R protein, a...
|
|
WO/2024/103110A1 |
The present disclosure relates to neuron derived extracellular vesicles and methods for their isolation as well as their use as biomarkers, including for neurodegenerative and/or neuropsychiatric diseases. The present disclosure also rel...
|
|
WO/2024/103636A1 |
The present invention belongs to the technical field of biology, and relates to new use of a gene, and particularly, to a protein for controlling the symbiotic nitrogen fixation efficiency of a soybean, a gene, an editing vector thereof,...
|
|
WO/2024/105656A1 |
HER receptor derived peptides are provided. Accordingly there is provided a composition of matter comprising a peptide comprising an amino acid sequence of a nuclear localization sequence (NLS) of a HER receptor capable of binding a nucl...
|
|
WO/2024/107784A2 |
CRISPR-Cas9 is a useful tool for creating precise genetic knock-in alterations through homology-directed repair (HDR), although all current methods rely on provision of an exogenous repair template. Disclosed herein are compositions, sys...
|
|
WO/2024/105663A1 |
The present application relates to a transgenic plant comprising an integrated host gene capable of being expressed in the plant, the host gene comprising an artificial mirtron capable of silencing a target gene and having a sequence com...
|
|
WO/2024/108092A1 |
Provided herein are methods of delivering "split" prime editors into a cell, e.g., via a recombinant adeno-associated virus (rAAV), to form a complete and functional prime editor. The prime editor may be split into two sections or three ...
|
|
WO/2024/107105A1 |
There is provided a recombinant cell comprising a plasmid expressing terpenoid synthase gene and one or more modification to the gene of the recombinant cell. Also provided is a recombinant cell for use in biosynthesis and a method of pr...
|
|
WO/2024/108088A1 |
The present disclosure relates to antibodies that bind to and agonize human LAG-3, and to bispecific antibodies that bind to and agonize each of human PD-1 and human LAG-3.
|
|
WO/2024/107551A1 |
Novel approaches to the treatment of pulmonary hypertension and methods for measuring or assessing the effectiveness of such treatments are provided. More specifically, novel approaches to the diagnosis/prognosis and treatment of PH asso...
|
|
WO/2024/107673A1 |
Compositions and methods and for enhancing the resistance of soybean plants to Asian soybean rust caused by one or more races of Phakopsora pachyrhizi are provided. The compositions comprise nucleic acid molecules encoding resistance (R)...
|
|
WO/2024/107006A1 |
One of the embodiment of the present invention relates to a fusion protein including a polypeptide represented by Formula (I) and a polypeptide represented by Formula (II) or a dimer thereof. The fusion protein according to the present i...
|
|
WO/2024/107119A1 |
Reported is the construction of a T3 vector expression system for the generation of inducible stable cell lines producing a range of recombinant proteins such as antibodies and their derivatives. It combines doxycyclin-inducible expressi...
|
|
WO/2024/104431A1 |
Provided are an antibody that specifically recognizes FRα or an antigen-binding fragment thereof, as well as a corresponding nucleic acid, a host cell, a drug, treatment and diagnosis methods, or a use.
|
|
WO/2024/104569A1 |
The present invention relates to a tomato plant having improved insect resistance, more specifically whitefly or mite resistance, wherein the plant comprises a ASAT3 gene encoding for an acetyl-CoA–dependent acyltransferase enzyme and ...
|
|
WO/2023/196658A3 |
Provided herein are methods using machine learning to predict protein variants that are likely to occur in nature. Such variants can be used (selected) to improve properties of the proteins. Also provided herein are antibodies and antige...
|
